Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: A phase II study in patients with HER2-negative metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 2, 2012, Pages 331-338

  Yoshimoto, Masataka ^a   Takao, Shintaro ^b   Hirata, Masaru ^c   Okamoto, Yasushi ^d   Yamashita, Sumio ^e   Kawaguchi, Yoshihiro ^f   Takami, Makoto ^g   Furusawa, Hidemi ^h   Morita, Satoshi ⁱ   Abe, Chigusa ^j   Sakamoto, Junichi ^k  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b HYOGO CANCER CENTER   (Japan)

^c JR Tokyo General Hospital   (Japan)

^d TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^e Fukaya Red Cross Hospital   (Japan)

^f GIFU UNIVERSITY HOSPITAL   (Japan)

^g TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^h Breastopia Namba Hospital   (Japan)

ⁱ YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^j Nonprofit Organization Epidemiological and Clinical Research Information Network   (Japan)

^k NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Capecitabine; Cyclophosphamide; Metastatic breast cancer; Metronomic chemotherapy; Oral combination

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOXIFLURIDINE; FLUOROURACIL; HEMOGLOBIN; TAXANE DERIVATIVE; UFT;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; DIARRHEA; DIZZINESS; DRUG RESPONSE; DYSGEUSIA; EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE METASTATIC BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; FOLLOW UP; HAND FOOT SYNDROME; HEART PALPITATION; HUMAN; HYPERPIGMENTATION; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; METRONOMIC DRUG ADMINISTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 84866553726     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1826-x     Document Type: Article

References (31)

1. Early Breast Cancer Trialist Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717
2. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP (2008) Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 100:1780-1791
3. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, Hortobagyi GN (1999) Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: A reference. Cancer 85:104-111
4. Hortobagyi GN (2002) Can we cure limited metastatic breast cancer? J Clin Oncol 20:620-623
5. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, Bertolini F (2006) Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108:452-459
6. Pasquier E, Kavallaris M, André N (2010) Metronomic chemotherapy: New rationale for new directions. Nat Rev Clin Oncol 7:455-465
7. Kamen BA, Rubin E, Aisner J, Glatstein E (2000) High-time chemotherapy or high time for low dose. J Clin Oncol 18:2935-2937
8. Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045-1047
9. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drugresistant cancer. Cancer Res 60:1878-1886
10. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W, Heldin CH (1989) Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338:557-562
11. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4:1013-1019
12. Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H, Tanaka Y (1999) Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 50-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 83:127-134
13. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823
14. Blum JL, Dees EC, Chacko A, Doane L, Ethirajan S, Hopkins J, McMahon R, Merten S, Negron A, Neubauer M, Ilegbodu D, Boehm KA, Asmar L, O'Shaughnessy JA (2006) Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 24:4384-4390
15. Endo M, Fujimoto-Ouchi K, Matsumoto T, Tanaka Y, Ishitsuka H (1997) Efficacy of combination chemotherapy of cyclophosphamide and 50-deoxy-5-fluorouridine in a mammary tumor xenograft model, MX-1. Jpn J Cancer Chemother 24:1295-1301
16. Yoshimoto M, Tada K, Tokudome N, Kutomi G, Tanabe M, Goto T, Nishimura S, Makita M, Kasumi F (2003) The potential for oral combination chemotherapy of 50-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer. Br J Cancer 89:1627-1632
17. Ebi H, Sigeoka Y, Saeki T, Kawada K, Igarashi T, Usubuchi N, Ueda R, Sasaki Y, Minami H (2005) Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 50-deoxy-5-fluorouridine (50-DFUR). Cancer Chemother Pharmacol 56:205-211
18. Ohno S, Mitsuyama S, Tamura K, Nishimura R, Tanaka M, Hamada Y, Kuroki S, Kyushu Breast Cancer Study Group (2007) Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer. Anticancer Res 27:1009-1013
19. Common Terminology Criteria for Adverse Events (CTCAE v3.0) (2004) 2003 (Japanese translation JCOG/JCSP version, 2004) Int J Clin Oncol 9(Suppl III):1-82 (in Japanese)
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
21. Kusama M, Nomizu T, Aogi K, Yoshimoto M, Horikoshi N, Tabei T, Noguchi S, Miura S, Yoshimura N, Kimura M, Toyama K, Shin E (2010) Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer. Breast Cancer 17:233-240
22. Banna GL, Simonelli M, Santoro A (2007) High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: A critical review. Curr Stem Cell Res Ther 2:65-82
23. Epstein RJ (1999) Drug-induced DNA damage and tumor chemosensitivity. J Clin Oncol 8:2062-2084
24. Goss PE, Chambers AF (2010) Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 10:871-877
25. O'Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10:20-29
26. Tanaka Y, Eda H, Fujimoto K, Tanaka T, Ishikawa T, Ishitsuka H (1990) Anticachectic activity of 50-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res 50:4528-4532
27. Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Hogel B, Darb-Esfahani S, Mehta K, Loibl S (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: Overall results from the GeparTrio study. Breast Cancer Res Treat 124:133-140
28. Hall C, Krishnamurthy S, Lodhi A, Mosalpuria K, Kuerer HM, Meric-Bernstam F, Bedrosian I, Hunt KK, Lucci A (2010) Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol 17:3252-3259
29. Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Takatsuka Y, Japan Breast Cancer Research Group (JBCRG) (2008) Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 110:531-539
30. Albain KS, Paik S, van't Veer L (2009) Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 18(Suppl 3):S141-S145
31. Piccart MJ (1999) Integration of new therapies into management of metastatic breast cancer: A focus on chemotherapy, treatment selection through use of molecular markers, and newly developed biologic therapies in late clinical development. ASCO Educ Book, pp 526-539